CYTK
Cytokinetics, Incorporated
$61.23
-1.76%
2026-10-23
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Key Fundamentals
Forward P/E
-14.52
EPS (TTM)
$-7.22
Revenue Growth (YoY)
-57.1%
Profit Margin
0.0%
Price/Book
-51.73
Beta
0.36
Market Cap
$8.99B
Avg Volume (10D)
2.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$81.77
60D Low
$59.78
Avg Volume
2.0M
Latest Close
$61.23
Get breakout alerts for CYTK
Sign up for Breakout Scanner to receive daily notifications when CYTK triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Cytokinetics, Incorporated (CYTK) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CYTK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CYTK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.